Publisher
Media Sphere Publishing Group
Subject
Psychiatry and Mental health,Neurology (clinical)
Reference70 articles.
1. Subei AM, Ontaneda D. Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. CNS Drugs. 2015;29(9):759-771. doi 10.1007/s40263-015-0277-4
2. Habirov FA, Devlikamova FI, Hajbullin TI, Babicheva NN. Pathogenetic heterogeneity of multiple sclerosis: a key to understanding the clinical polymorphism of the disease and the development of individualized therapy. Nevrologicheskij vestnik. 2010;1:54-65. (In Russ.).
3. Scott LJ. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. CNS Drugs. 2013;27:971-88. doi 10.1007/s40263-013-0117-3
4. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011;25:401-414. doi 10.2165/11588120-000000000-00000
5. Fricker J. The copolymer-1 story so far. Lancet. 1998;351:1792. doi 10.1016/s0140-6736(05)78758-4
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献